Open access
Jul 2026
Rivaroxaban plus antiplatelet therapy for coronary artery ectasia: 36-month outcomes and risk prediction from a retrospective cohort study
In patients with CAE, low-dose rivaroxaban combined with single antiplatelet therapy was associated with lower long-term MACE risk without a significant increase in major bleeding.
Meng Feng, Yun-Jie Wu, Chaoqing Xie et al.
· Frontiers in Cardiovascular... · 0 citations